Default company panoramic image

Omni Bio Pharmaceutical, Inc.

Early-stage biopharmaceutical company in development of a recombinant version of a natural protein for treatment of a variety of diseases.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Denver, CO, USA
  • Currency USD
  • Founded February 2006
  • Employees 3
  • Website

Company Summary

Omni is in preclinical development of a recombinant form of alpha-1 antitrypsin (“AAT”). AAT is an FDA-approved treatment for "AAT-deficiency," which is a market of approximately $600 million wordwide. Our recombinant form has been shown to be 40-50x more potent than native AAT. We believe our recombinant form would be a highly competitive drug to native AAT in terms of efficacy, cost to manufacture, selling price and route of administration.


  • Default avatar
    Robert Ogden
    Chief Financial Officer

    Mr. Ogden has served as our Chief Financial Officer, Treasurer and Secretary since May 2009. He has over 20 years senior financial management experience with micro-cap entities. Mr. Ogden began his career as a public accountant with PricewaterhouseCoopers LLP and is a CPA.

  • Default avatar
    Bruce Schneider
    Chief Executive Officer and Director

    Dr. Schneider has served as our Chief Executive Officer and as a member of our Board since January 2013. From 2009 to 2010, he was employed by Pfizer as Executive Vice President & R&D Integration Lead. From 1972-2009, he was employed by Wyeth Research where he held numerous senior-level R&D positions, including Executive Vice President & Chief of Operations and Senior Vice President, Research Operations & Planning.

  • Default avatar
    Charles Dinarello
    Chief Scientific Officer

    Dr. Dinarello has served as our Chief Scientific Officer since March 2011 and served as our Acting Chief Executive Officer and a member of our Board from 2009 to 2011. He currently serves as Professor of Medicine and Immunology at the University of Colorado Denver. Dr. Dinarello is recognized as a "founding father" of cytokine biology and has received numerous US and international scientific awards in this area.

  • Default avatar
    Bruce Forrest
    Product and Business Development Lead

    Dr. Forrest has served as a part-time business and scientific consultant since October 2012 and is leading our business development efforts with the current AAT manufacturers. As President of B D Forrest & Company, he consults with several biopharmaceutical companies in various therapeutic areas. Dr. Forrest brings over 25 year experience in immunology, drug development, and licensing and sales transactions.

  • Default avatar
    Michael Kamarck
    Consultant and Director

    Dr. Kamarck has served as a member of our Board and a consultant since January 2013. From 2010 to 2012, he was employed by Merck as President of Merck BioVentures and Senior Vice President of Vaccines and Biologics Manufacturing. From 2001 to 2009, he was employed by Wyeth and held various senior executive positions, including President, Technical Operations and Product Supply and was responsible for all global technical operations.


  • Default avatar
    Faegre Baker Daniels LLP; Perkins Coie LLP
    Default avatar
    Hein & Associates LLP

Previous Investors

  • Default avatar
    Information is available in our reports as filed with the SEC